-
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol. 2024 Jun; 23(6):588-602.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL, N-MOmentum study investigators. PMID: 38760098.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2023 09; 94(9):757-768.
Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BA, N-MOmentum study investigators. PMID: 37221052; PMCID: PMC10447388.
View in:
PubMed Mentions:
11 Fields:
Translation:
Humans
-
Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder". Neurol Ther. 2022 Sep; 11(3):1439-1443.
Cree BAC, Greenberg B, Cameron C, Weinshenker BG. PMID: 35779190; PMCID: PMC9338188.
View in:
PubMed Mentions:
3
-
Secondary Progressive Multiple Sclerosis: New Insights. Neurology. 2021 08 24; 97(8):378-388.
Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Pozo Ramajo A, Murphy N, Lassmann H. PMID: 34088878; PMCID: PMC8397587.
View in:
PubMed Mentions:
71 Fields:
Translation:
Humans
-
Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Mult Scler Relat Disord. 2021 Jul; 52:103010.
Cree BAC, Pradhan A, Pei J, Williams MJ, OPERA I and OPERA II clinical investigators. PMID: 34147885.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. Mult Scler. 2021 08; 27(9):1432-1441.
Romeo AR, Rowles WM, Schleimer ES, Barba P, Hsu WY, Gomez R, Santaniello A, Zhao C, Pearce JR, Jones JB, Cree BC, Hauser SL, Gelfand JM, Stewart WF, Goodin DS, Bove RM. PMID: 33236967; PMCID: PMC8144241.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020 12; 19(12):988-997.
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD, SPI2 investigative teams. PMID: 33222767.
View in:
PubMed Mentions:
38 Fields:
Translation:
HumansCTClinical Trials
-
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 10 12; 394(10206):1352-1363.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E, N-MOmentum study investigators. PMID: 31495497.
View in:
PubMed Mentions:
231 Fields:
Translation:
HumansCTClinical Trials
-
Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. Ann Neurol. 2018 07; 84(1):51-63.
Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE. PMID: 29908077; PMCID: PMC6119489.
View in:
PubMed Mentions:
21 Fields:
Translation:
Humans
-
Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach? J Neuroophthalmol. 2018 06; 38(2):258-262.
Cree BAC. PMID: 29750736.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial. Ther Adv Neurol Disord. 2018; 11:1756286418774338.
Cree BAC, Arnold DL, Cascione M, Fox EJ, Williams IM, Meng X, Schofield L, Tenenbaum N. PMID: 29844796; PMCID: PMC5964857.
View in:
PubMed Mentions:
10
-
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 04 24; 90(17):789-800.
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. PMID: 29686117.
View in:
PubMed Mentions:
51 Fields:
Translation:
Humans
-
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 04 24; 90(17):777-788.
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. PMID: 29686116.
View in:
PubMed Mentions:
188 Fields:
Translation:
Humans
-
Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018 05 15; 90(20):e1815-e1821.
Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M. PMID: 29669908; PMCID: PMC5957303.
View in:
PubMed Mentions:
59 Fields:
Translation:
Humans
-
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler. 2016 06; 22(7):862-72.
Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. PMID: 26666258; PMCID: PMC4904355.
View in:
PubMed Mentions:
28 Fields:
Translation:
Humans
-
Placebo controlled trials in neuromyelitis optica are needed and ethical. Mult Scler Relat Disord. 2015 Nov; 4(6):536-45.
Cree BA. PMID: 26590660.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Genetics of primary progressive multiple sclerosis. Handb Clin Neurol. 2014; 122:211-30.
Cree BA. PMID: 24507520.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansAnimals
-
Acute inflammatory myelopathies. Handb Clin Neurol. 2014; 122:613-67.
Cree BA. PMID: 24507538.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansAnimalsPHPublic Health
-
Multiple sclerosis genetics. Handb Clin Neurol. 2014; 122:193-209.
Cree BA. PMID: 24507519.
View in:
PubMed Mentions:
17 Fields:
Translation:
HumansAnimals
-
Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013 Jun; 19(7):835-43.
Cree BA. PMID: 23319073.
View in:
PubMed Mentions:
21 Fields:
Translation:
Humans
-
Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011 Apr; 68(4):464-8.
Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. PMID: 21482925.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug; 68(2):145-50.
Cree BA, Kornyeyeva E, Goodin DS. PMID: 20695007.
View in:
PubMed Mentions:
41 Fields:
Translation:
Humans
-
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS One. 2010 Jun 25; 5(6):e11296.
Cree BA, Rioux JD, McCauley JL, Gourraud PA, Goyette P, McElroy J, De Jager P, Santaniello A, Vyse TJ, Gregersen PK, Mirel D, Hafler DA, Haines JL, Pericak-Vance MA, Compston A, Sawcer SJ, Oksenberg JR, Hauser SL, IMAGEN, IMSGC. PMID: 20593013; PMCID: PMC2892470.
View in:
PubMed Mentions:
28 Fields:
Translation:
Humans
-
Multiple sclerosis susceptibility alleles in African Americans. Genes Immun. 2010 Jun; 11(4):343-50.
Johnson BA, Wang J, Taylor EM, Caillier SJ, Herbert J, Khan OA, Cross AH, De Jager PL, Gourraud PA, Cree BC, Hauser SL, Oksenberg JR. PMID: 19865102; PMCID: PMC2880217.
View in:
PubMed Mentions:
54 Fields:
Translation:
Humans
-
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol. 2009 Feb; 66(2):226-33.
Cree BA, Reich DE, Khan O, De Jager PL, Nakashima I, Takahashi T, Bar-Or A, Tong C, Hauser SL, Oksenberg JR. PMID: 19204159; PMCID: PMC4334456.
View in:
PubMed Mentions:
43 Fields:
Translation:
Humans
-
Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep. 2008 Sep; 8(5):427-33.
Cree B. PMID: 18713580.
View in:
PubMed Mentions:
19 Fields:
Translation:
HumansAnimals
-
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006 Sep 15; 15(18):2813-24.
Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F, Cree BC, Begovich AB, Villoslada P, Montalban X, Uccelli A, Savettieri G, Lincoln RR, DeLoa C, Haines JL, Pericak-Vance MA, Compston A, Hauser SL, Oksenberg JR. PMID: 16905561.
View in:
PubMed Mentions:
122 Fields:
Translation:
HumansCells
-
A fatal case of coxsackievirus B4 meningoencephalitis. Arch Neurol. 2003 Jan; 60(1):107-12.
Cree BC, Bernardini GL, Hays AP, Lowe G. PMID: 12533096.
View in:
PubMed Mentions:
20 Fields:
Translation:
HumansCells
-
Approved and future pharmacotherapy for multiple sclerosis. Neurologist. 2002 Sep; 8(5):290-301.
Stüve O, Cree BC, von Büdingen HC, Yousef S, Bowen JD, Genain CP, Hauser SL, Steinman L, Zamvil SS. PMID: 12803676.
View in:
PubMed Mentions:
4 Fields: